Key Speakers and Presentations released for the 14th Annual RNA Therapeutics Conference

LONDON - Dec. 12, 2022 - PRLog -- SAE Media Group's 14th Annual RNA Therapeutics Conference will welcome expert speakers from big pharma companies to bring together cutting-edge discussions in the developments and challenges in the RNA Therapeutics field. The conference will take place on 8 – 9 February 2023 in London UK – live and in person.

RNAi continues to be a key focus of the event, in combination with RNA AI modelling and the next generation of RNA novel RNA modalities, including self-amplifying RNAs, small activating RNAs, circular RNAs and long non-coding RNAs.

The RNA therapeutics conference this year will be covering an industry outlook of the RNA therapeutic field, a review of mRNA-based therapies, advancements in AI modelling, an update on RNAi and a more in-depth review of the next generation of novel RNA modalities.

Register by 16 December to save £100 and take advantage of the early bird offer via http://www.therapeutics-rna.com/PR3pelog

SAE Media Group have released a snapshot of the speakers and sessions that will be featured during the two-day conference, please see below:

Featured Key Conference Speakers:

• Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson
• Joseph Martinelli, Senior Director Genetic Medicine, Eli Lilly
• Ying Yu, Associated Director, AbbVie
• Martin Akerman, Chief Technical Officer, Envisagenics
• Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca
• Souphalone Luangsay, Senior Principal Scientist, Roche

Key Sessions include

AI/ML Developed RNA Therapeutics for Neurodegenerative Diseases

• Overcoming in-silico modeling challenges for neurodegenerative diseases
• How Envisagenics' SpliceCore platform can be used in designing antisense oligonucleotides
• Translational R&D from in-silico to in-vitro for potential ASO candidates in neurodegenerative diseases

Martin Akerman, Chief Technology Officer, Envisagenics

Genetic Medicine: State of The Art, Frontiers and Current Research

• Addressing key challenges at the forefront of the next generation of genetic medicines
• The role of Nucleic acid innovation in the development of RNA therapeutics
• Exploring delivery innovation as a crucial component in the advancement of RNA therapies

Joseph Martinelli, Executive Director, Eli Lilly

Visit the website to view the full agenda and speaker line-up at: http://www.therapeutics-rna.com/PR3prlog

Proudly sponsored by: Abzu, eTheRNA, Roche, Sartorius BIA Separations
Exhibitors: Euroapi, PolyPeptide, Symbiosis

For sponsorship enquiries contact Andrew Gibbons at
andrew.gibbons@saemediagroup.com or +44 (0) 20 7827 6156

For media enquiries contact Marketing, Lamprini Balasi at
lamprini.balasi@saemediagroup.com or +44 (0) 20 7827 6732

14th Annual RNA Therapeutics
8 – 9 February 2023
London, UK
#RNATx2023
Register by 16 December 2022 and SAVE £100!
http://www.therapeutics-rna.com/PR3prlog